Atomoxetine Hydrochloride
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Attention Deficit Hyperactivity Disorder
Conditions
Attention Deficit Hyperactivity Disorder
Trial Timeline
Jun 1, 2004 → Apr 1, 2006
NCT ID
NCT00191659About Atomoxetine Hydrochloride
Atomoxetine Hydrochloride is a phase 3 stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00191659. Target conditions include Attention Deficit Hyperactivity Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00216918 | Approved | Completed |
| NCT00191386 | Phase 3 | Completed |
| NCT00191659 | Phase 3 | Completed |
| NCT00485875 | Approved | Completed |
| NCT00485849 | Approved | Completed |
| NCT00485407 | Phase 3 | Completed |
| NCT00485628 | Phase 2 | Completed |
Competing Products
20 competing products in Attention Deficit Hyperactivity Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine + Placebo | Eli Lilly | Phase 2/3 | 65 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine Hydrochloride | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Phase 3 | 77 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine hydrochloride + Placebo | Eli Lilly | Approved | 85 |
| CLONICEL (Clonidine HCl sustained release) | Shionogi | Phase 3 | 77 |
| Donepezil hydrochloride + Placebo | Eisai | Phase 3 | 77 |
| LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule) | Eli Lilly | Phase 2/3 | 65 |
| Atomoxetine + Placebo | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Pre-clinical | 23 |
| Atomoxetine Hydrochloride | Eli Lilly | Approved | 85 |
| Atomoxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Atomoxetine Hydrochloride + Placebo | Eli Lilly | Approved | 85 |
| atomoxetine | Eli Lilly | Phase 3 | 77 |
| atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day | Eli Lilly | Phase 3 | 77 |
| Atomoxetine Hydrochloride | Eli Lilly | Approved | 85 |
| Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + Placebo | Eli Lilly | Phase 3 | 77 |